14 Result(s)
within
Bashkim Kadriu
English
-
Article
Ketamine in neuropsychiatric disorders: an update
The discovery of ketamine as a rapid-acting antidepressant led to a new era in the development of neuropsychiatric therapeutics, one characterized by an antidepressant response that occurred within hours or da...
-
Article
Open AccessComparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration
Subanesthetic-dose racemic (R,S)-ketamine (ketamine) produces rapid, robust, and sustained antidepressant effects in major depressive disorder (MDD) and bipolar disorder (BD) and has also been shown to effectivel...
-
Chapter
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics
The approval of ketamine for treatment-resistant depression has created a model for a novel class of rapid-acting glutamatergic antidepressants. Recent research into other novel rapid-acting antidepressants – ...
-
Article
The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response
Dysfunction in a wide array of systems—including the immune, monoaminergic, and glutamatergic systems—is implicated in the pathophysiology of depression. One potential intersection point for these three system...
-
Article
Open AccessKetamine modulates fronto-striatal circuitry in depressed and healthy individuals
Ketamine improves motivation-related symptoms in depression but simultaneously elicits similar symptoms in healthy individuals, suggesting that it might have different effects in health and disease. This study...
-
Article
Correction: Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
-
Article
Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression
A single, subanesthetic dose of (R,S)-ketamine (ketamine) exerts rapid and robust antidepressant effects. Several groups previously reported that (2S,6S;2R,6R)-hydroxynorketamine (HNK) had antidepressant effects ...
-
Article
Evaluating global brain connectivity as an imaging marker for depression: influence of preprocessing strategies and placebo-controlled ketamine treatment
Major depressive disorder (MDD) is associated with altered global brain connectivity (GBC), as assessed via resting-state functional magnetic resonance imaging (rsfMRI). Previous studies found that antidepress...
-
Article
Open AccessPrognosis and improved outcomes in major depression: a review
Treatment outcomes for major depressive disorder (MDD) need to be improved. Presently, no clinically relevant tools have been established for stratifying subgroups or predicting outcomes. This literature revie...
-
Article
Open AccessCorrection: Exploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression
Michael F. Grunebaum’s name was misspelled/misstated as “Gruenbaum M.F.” in the original Article. This has now been updated in the HTML and PDF versions of this Article.
-
Article
Open AccessExploratory genome-wide association analysis of response to ketamine and a polygenic analysis of response to scopolamine in depression
Growing evidence suggests that the glutamatergic modulator ketamine has rapid antidepressant effects in treatment-resistant depressed subjects. The anticholinergic agent scopolamine has also shown promise as a...
-
Article
Plasma metabolomic profiling of a ketamine and placebo crossover trial of major depressive disorder and healthy control subjects
(R,S)-Ketamine produces rapid, robust, and sustained antidepressant effects in major depressive disorder. Specifically, its pharmacological efficacy in treatment refractory depression is considered a major bre...
-
Article
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Clinical and preclinical studies suggest that dysfunction of the glutamatergic system is implicated in mood disorders such as major depressive disorder and bipolar depression. In clinical studies of individual...
-
Article
Selective α4β2 Nicotinic Acetylcholine Receptor Agonists Target Epigenetic Mechanisms in Cortical GABAergic Neurons
Nicotine improves cognitive performance and attention in both experimental animals and in human subjects, including patients affected by neuropsychiatric disorders. However, the specific molecular mechanisms u...
